Annabel Fowler Gatto launched her women's workwear company ahead of the pandemic. Here's how it went. Photo via Pexels

I realized a huge problem professional women were facing, and I launched a company to address it. But then, a pandemic hit.

Eight out of 10 women say they're frustrated and unsupported by traditional workwear brands and their offerings. For many, quality women's workwear means hefty price tags for clothes than, often, have unflattering silhouettes and difficult-to-maintain pieces. It's not a great experience.

Enter Suitably, a professional womenswear brand that offers seasonless staples—all machine washable and under $100. We launched in February 2020 with sky-high momentum. Then, six weeks later, COVID-19 shut down offices worldwide. Overnight, we saw a dip in traffic and the launch momentum slow. But we kept going — reinventing, reimaging, and engineering new ways to serve our customers during a pandemic who were, suddenly, working and interviewing from home. And, now, we're coming out the other side, a stronger, more dynamic and more customer-centric brand than ever. Here's what I learned from launching a workwear brand in a pandemic.

#1 — Be what your customers want and need 

Suitably isn't solely about fashion — it's about helping women be the best versions of themselves, personally and professionally. When COVID-19 struck, that need amplified among our core audience. From our interactions and proactive outreach we heard them loud and clear — they need help, support and guidance now.

We immediately shifted our focus from promoting the collection to doing everything we could to help our community. I made myself available for virtual coffee sessions and hosted over 100 of them during the pandemic. Next, we partnered with a good friend — a psychologist — and churned out free resources on everything from staying positive in a crisis to professional advice, life hacks and everything related to Zoom, from how to dress for a Zoom meeting in every industry to basic Zoom etiquette. The groundswell was immediate and powerful — women craved this information and this connection.

#2 — Be a voice for change

Weeks into the shutdowns when the global workforce was isolated and sweatpants-clad, we launched our next campaign, #GetUpGetDressed. So many women had shared their stories and told us they could barely get out of bed in the morning let alone get dressed and get motivated.

By encouraging women to #GetUpGetDressed — and to share their work-from-home style with Suitably's community — we knew we were doing more than promoting style. We were powering them to shake off the stress and fear, put on something that made them feel good and connect with other women in the Suitably community. Hundreds of women participated and the positive feedback we received was unparallelled. With that, our social footprint grew even more.

#3 — Be careful whose advice you take

Despite the positivity from our community, we still had the naysayers — people eager to share their unsolicited commentary on what we should be doing. The general consensus? Shut down or pivot Suitably ASAP — that a business like ours would likely never be relevant again. We were told to make "Zoom tops." We were told to explore athleisure and masks. We were told to wait for a vaccine then start over — to abandon everything we'd done, the brand equity we worked so hard to build and achieved or pause until the "world is normal".

The reality? None of those people were part of Suitably — and, like us, none of them knew how to navigate a global pandemic. Even so, it would have been easy to fall in line and let a knee-jerk moment of panic destroy everything we'd built. But, instead, we took a breath, took a beat and promised to drown out the noise and the negativity so we could move the business forward, putting the needs of our community first.

#4 — Be confident in yourself

Without the noise we were better able to reassess where we were and what came next — to go back to our roots and to the customer listening we'd been doing for the last few months and use that to set a new course. We knew there was light out there somewhere, and that if we just kept moving towards it, we'd find success.

Admittedly, that was hard sometimes. Even though I knew we had our finger on the pulse of our customers' wants and needs, every day brought a new learning. Despite the chaos, we pushed ahead, following our customers' lead. By the end of June, we had significant data to show that many women in our community, especially those outside of the tri-state area, were returning to the workplace or shopping in anticipation of returning to the workplace. We started to get customer chat's every day asking when new products would be launched, when our restock for sold out pieces was going to occur and we knew it was time to ramp Suitably 100 percent back up.

#5 — Be there for every step of the journey

While the customer journey is rarely linear, the pandemic brought new levels of uncertainty and disconnect. Based on the success of our support and engagement initiatives, we continued to follow our audience on their path — a path that, for many, led right back to the office. We immediately ramped up our messaging, with an eye on helping women get ready to go back — and to feel confident and ready for action the minute they walked through the office doors.

Because of the foundation we'd laid during those first few months — a foundation anchored in trust, understanding and support — our audience leaned in, ready to take that next step into the Suitably experience. Quickly, we were just about back to where we were before COVID-19, not just providing actionable content and a friendly ear but, also, amazing wardrobe pieces that made her feel empowered whether she was back in the office of working from home.

No one knows how to navigate a pandemic — but we all know how to build relationships. That, ultimately, was our strategy. And that, ultimately, is what helped us steer Suitably through the peak of the crisis so we could come out the other side a better, stronger, more dynamic brand than I ever could have imagined with a loyal audience who knows we're truly committed to them and to their success.

------

Born and raised in Houston, Annabel Fowler Gatto is the co-founder and CEO of New York-based Suitably.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.